Nubeqa (darolutamide)

pCPA File Number: 22191

Negotiation Status:

Active Negotiation

Indication(s):

For the treatment of patients with metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel

Sponsor/Manufacturer:

Bayer Inc.

CADTH Project Number:

PC0294

pCPA Engagement Letter Issued:

2023-09-20

Negotiation Process Concluded:

Not Applicable